# EDGAR Filing Document

**Accession Number:** 0001933414
**File Stem:** 0001628280-23-002537
**Filing Date:** 2023-2
**Character Count:** 2520
**Document Hash:** 74883533c33266926665e018df8dca1c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-23-002537.hdr.sgml**: 20230310

**ACCESSION NUMBER**: 0001628280-23-002537

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230207

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Mineralys Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001933414
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 150 N. RADNOR CHESTER ROAD
- **STREET 2:** SUITE F200
- **CITY:** RADNOR
- **STATE:** PA
- **ZIP:** 19087
- **BUSINESS PHONE:** (888) 378-6240

**MAIL ADDRESS:**
- **STREET 1:** 150 N. RADNOR CHESTER ROAD
- **STREET 2:** SUITE F200
- **CITY:** RADNOR
- **STATE:** PA
- **ZIP:** 19087

**Mineralys Therapeutics, Inc.**

**150 N. Radnor Chester Road, Suite F200**

**Radnor, PA 19087**

February 7, 2023

**<u>VIA EDGAR</u>**

Office of Life Sciences

Division of Corporation Finance

U.S. Securities and Exchange Commission

100 F Street N.E.

Washington, D.C. 20549

---

| | |
|:---|:---|
| **Re:** | **Mineralys Therapeutics, Inc.** |
| | **Registration Statement on Form S-1, as amended** |
| | **File No. 333-269282** |

---

Ladies and Gentlemen:

Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Mineralys Therapeutics, Inc. (the "***Company***"), respectfully requests that the effective date of the Registration Statement on Form S-1 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on February 9, 2023, or as soon as practicable thereafter.

Please contact Matthew T. Bush of Latham & Watkins LLP, counsel to the Company, at (858) 523-3962, to provide notice of effectiveness, or if you have any questions or require additional information regarding this matter. Thank you for your assistance and cooperation in this matter.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| MINERALYS THERAPEUTICS, INC. | MINERALYS THERAPEUTICS, INC. |
| By: | /s/ Jon Congleton |
|  | Jon Congleton |
|  | Chief Executive Officer |

---

---

| | |
|:---|:---|
| cc: | Adam Levy, *Mineralys Therapeutics, Inc.* |
| | Cheston J. Larson, *Latham & Watkins LLP* |
| | Matthew T. Bush, *Latham & Watkins LLP* |
| | Ilir Mujalovic, *Shearman & Sterling LLP* |

---

<br>